Analytical Data
-
Gene name
GPR84
- Application
-
Alternative Names
Inflammation-related G-protein coupled receptor EX33
-
Species
Human
-
Source
Yeast
-
Tag
C- hFc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NQS5
-
Expression Region
1-26aa
-
Molecular Weight
31.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GPR84 is a G protein-coupled receptor (GPCR) that has garnered increasing attention in recent years due to its role in modulating immune responses and inflammation. Originally identified as a receptor for medium-chain fatty acids, GPR84 is primarily expressed in immune cells, including macrophages and neutrophils, suggesting its potential involvement in various inflammatory diseases. The receptor has been implicated in the regulation of cytokine production and has been associated with conditions such as asthma, inflammatory bowel disease, and obesity. The study of GPR84 and its signaling pathways offers promising avenues for therapeutic interventions targeting inflammation and immune dysregulation. Recombinant GPR84 proteins have been developed for functional assays and structural studies to elucidate the receptor’s mechanism of action. Understanding the ligand binding properties and downstream signaling cascades of GPR84 may pave the way for novel anti-inflammatory drugs that could improve treatment strategies for immune-related disorders. Ongoing research focuses on the development of specific agonists and antagonists that could modulate GPR84 activity, revealing its potential as a biomarker for disease progression and a target for drug discovery.
